Shares of Corium International Inc. (NASDAQ:CORI) traded down 4% during trading on Thursday . The stock traded as low as $4.48 and last traded at $4.53, with a volume of 83,557 shares traded. The stock had previously closed at $4.72.

Several analysts have commented on the stock. FBR & Co reaffirmed a “buy” rating on shares of Corium International in a research report on Monday, May 2nd. Zacks Investment Research lowered shares of Corium International from a “buy” rating to a “hold” rating in a research report on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Corium International in a research report on Thursday, June 23rd. Jefferies Group reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Corium International in a research report on Wednesday, May 11th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Corium International in a research report on Wednesday, May 18th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $11.92.

The stock’s 50 day moving average is $4.17 and its 200-day moving average is $4.40. The firm’s market cap is $98.51 million.

Corium International (NASDAQ:CORI) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.08. On average, equities research analysts expect that Corium International Inc. will post ($1.63) EPS for the current year.

In other Corium International news, Director Eric Bjerkholt purchased 24,500 shares of the stock in a transaction dated Thursday, May 19th. The shares were bought at an average cost of $3.64 per share, with a total value of $89,180.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Corium International, Inc is a biopharmaceutical company. The Company is engaged in the development, manufacture and commercialization of specialty pharmaceutical products that focuses on transdermal and transmucosal delivery systems. Its development platforms enable transdermal delivery of large molecules, or biologics, including vaccines, peptides and proteins, as well as small molecules.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.